Anti-S1P strategies could not only provide a beneficial therapeutic option in ccRCC, but also in other cancers as the role of HIF-2 as an oncoprotein might extend beyond renal carcinomas. The gene discussed is MBTPS1; the disease is nonpapillary renal cell carcinoma.